“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.Hans‐Joachim Schmoll, Alexander Stein, Stephan Kanzler et al.|Journal of Clinical Oncology|2017Cited by 19
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trialHans‐Joachim Schmoll, Joseph Tintelnot, Julia Mann et al.|British Journal of Cancer|2023Cited by 11
CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209).Hans‐Joachim Schmoll, Alexander Stein, Benjamin Garlipp et al.|Journal of Clinical Oncology|2017Cited by 9
Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.Julia Quidde, Alexander Stein, Hans‐Joachim Schmoll et al.|Journal of Clinical Oncology|2017Cited by 2
FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)Hans‐Joachim Schmoll, Alexander Stein, Benjamin Garlipp et al.|Annals of Oncology|2016Cited by 1